SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schulz, R.
Right arrow Articles by Heusch, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schulz, R.
Right arrow Articles by Heusch, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: AT 1-receptor blockade in experimental myocardial ischaemia/reperfusion

Rainer Schulz

Abteilung für Pathophysiologie, Zentrum für Innere Medizin des Universitätsklinikums Essen, Germany

Gerd Heusch

Abteilung für Pathophysiologie, Zentrum für Innere Medizin des Universitätsklinikums Essen, Germany, gerd.heusch{at}uni-essen.de

Key Words: renin-angiotensin-aldosterone system • AT1-receptor • AT2-receptor • myocardial ischaemia • reperfusion

References

  • Linder C., Heusch G.: ACE inhibitors for the treatment of myocardial ischemia? Cardiovasc Drugs Ther 1990;4:1375-84.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindpaintner K., Wilhelm MJ, Jin M. et al. Tissue renin-angiotensin systems: Focus on the heart. J Hypertens 1987;5 (suppl 2):S33-S38.[Web of Science]
  • HirschAT,Talsness CE, Schunkert H., Paul M., Dzau VJ Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475-82.[Abstract/Free Full Text]
  • Danser,AHJ Saris JJ, Schuijt MP, van Kats JP: Is there a local renin-angiotensin system in the heart? Cardiovasc Res 1999;44:252-65.[Abstract/Free Full Text]
  • Ertl G., Kloner RA,Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8.[Free Full Text]
  • McAlpine HM, Cobbe SM Neuroendocrine changes in acute myocardial infarction. Am J Med 1988;84 (suppl 3A):61-6[CrossRef][Medline] [Order article via Infotrieve]
  • Noda K., Sasaguri M., Ideishi M., Ikeda M.,Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 1993;27: 334-40.[Abstract/Free Full Text]
  • Balcells E., Meng QC, Johnson J.r. WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;42:H1769-H1774.
  • Hollenberg NK Implications of species difference for clinical investigation. Studies on the renin-angiotensin system. Hypertension 2000;35 [part 2]:150-4.[Abstract/Free Full Text]
  • Baumgarten CR, Linz WL, Kunkel G., Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993;108:293-5.[Web of Science][Medline] [Order article via Infotrieve]
  • Timmermans Pbmwm, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.[Web of Science][Medline] [Order article via Infotrieve]
  • Paradis P., Dali-Youcef N., Paradis FW,Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 2000;97:931-6.[Abstract/Free Full Text]
  • Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt RE, Dzau VJ Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993;268:24539-42.[Abstract/Free Full Text]
  • Scheuer DA, Perrone MH Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993;33:R917-R923.
  • Akishita M.,Yamada H., Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking angiotensin II Type 2 receptor. Biochem Biophys Res Commun 1999;261:345-9. 16. HunleyTE, Tamura M., Stoneking BJ et al.The angiotensin type II receptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice. Kidney Int 2000;57:570-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Stoll M., Steckelings UM, Bottari SP, Metzger R., UngerT. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Hübner R., Högemann AM, Sunzel M., Riddell JG Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11(Suppl 2):S19-S25.
  • Liu Y.-H, Yang X.-P, Sharov VG, Nass O., Sabbah HH, Peterson E., Carretero OA Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-35.[Web of Science][Medline] [Order article via Infotrieve]
  • Wiemer G., Schölkens BA, Busse R., Wagner A., Heitsch H., Linz W. The functional role of angiotensin II-subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 1993;3:24-7.
  • Seyedi N., Xu XB, Nasjletti A., Hintze TH Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26:164-70.[Abstract/Free Full Text]
  • Carey RM, Jin X.-H, Wang Z.-Q, Siragy HM Nitric oxide: a physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand 2000;168:65-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kuga T., Mohri M., Egashira K. et al. Bradykinin-induced vasodilation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol 1997;30:108-12.[Abstract]
  • Martorana PA, Kettenbach B., Breipohl G., Linz W., Schölkens BA Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990;182:395-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Werrmann JG, Cohen SM Comparison of effects of angiotensin-converting enzyme inhibition with those of angiotensin II receptor antagonism on functional and metabolic recovery in postischemic working rat heart as studied by [31P] nuclear magnetic resonance. J Cardiovasc Pharmacol 1994;24:573-86.[Web of Science][Medline] [Order article via Infotrieve]
  • Werrmann JG, Cohen SM Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion. J Cardiovasc Pharmacol 1996;27:177-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Paz Y., Gurevitch J., Frolkis I. et al. Effects of an angiotensin II antagonist on ischemic and nonischemic isolated rat hearts. Ann Thorac Surg 1998;65:474-9.[Abstract/Free Full Text]
  • Ford WR, Clanachan AS, Jugdutt BI Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996;94:3087-9.[Abstract/Free Full Text]
  • Massoudy P., Becker BF, Gerlach E. Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat. J Cardiovasc Pharmacol 1994;23:632-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Dörge H., Behrends M., Schulz R., Jalowy A., Heusch G. Attenuation of myocardial stunning by AT1receptor antagonist candesartan. Basic Res Cardiol 1999;94:208-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • van Gilst WH, de Graeff PA, Wesseling H., de Langen CDJ. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors:A comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol 1986;8:722-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Ehring T.,Baumgart D., Krajcar M., Hümmelgen M., Kompa S., Heusch G. Attenuation of myocardial stunning by the ACE-inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins, but not nitric oxide. Circulation 1994;90:1368-85.[Abstract/Free Full Text]
  • Hohlfeld T., Strobach H., Schrör K. Stimulation of prostacyclin synthesis by defibrotide: Improved contractile recovery from myocardial `stunning`. J Cardiovasc Pharmacol 1991;17:108-15.[Medline] [Order article via Infotrieve]
  • Shimizu M., Wang Q.-D, Sjöquist P-O., Rydén L. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts. J Cardiovasc Pharmacol 1999;34:78-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yoshiyama M., Kim S., Yamagishi H. et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994;128:1-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wang Q.-D. Sjöqist P-O. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol 1999;380:13-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hoshida S., Yamashita N., Kuzuya T., Hori M. Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits. Atherosclerosis 2000;149:287-94.[Medline] [Order article via Infotrieve]
  • Preckel B., Schlack W., González M., Obal D., Bathel H., Thämer V. Influence of the angiotensin II AT1 receptor antagonist irbesartan on ischemia/reperfusion injury in the dog heart. Basic Res Cardiol 2000;95:404-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hartman JC, Hullinger TG, Wall TM, Shebuski RJ Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993;234:229-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Liu Y., Tsuchida A., Cohen MV, Downey JM Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995;27:883-92.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Diaz RJ, Wilson GJ Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol 1997;29:129-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shimizu M.,Wang Q.-D, Sjöquist P-O., Ryden L. Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol 1998;32:231-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shimizu M., Wang Q.-D, Sjöquist P-O., Rydén L. The angiotensin II AT1 receptor antagonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion. Cardiovasc Drugs Ther 1999;13:347-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shimizu M.,Wang Q.-D, Sjöquist P-O., Ryden L. Combination of a calcium antagonist, a lipid peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. J Cardiovasc Pharmacol 1999;34:512-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • JalowyA, Schulz R., Dörge H., Behrends M., Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol 1998;32:1787-96.[Abstract/Free Full Text]
  • Weidenbach R., Schulz R., Gres P., Behrends M., Post H., Heusch G. Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT1-receptor antagonism. BrJPharmacol 2000; 131:138-44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Liu Y.-H, Yang X.-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996;27:7-13.[Abstract/Free Full Text]
  • Sladek T., Sladkova J., Kolar F. et al. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 1996;31:568-76.[Abstract/Free Full Text]
  • Richard V., Ghaleh B., Berdeaux A., Giudicelli J-F. Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993;110:969-74.[Web of Science][Medline] [Order article via Infotrieve]
  • Zhu B.-Q, Sun Y.-P, Sievers RE et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol 2000;35:787-95.[Abstract/Free Full Text]
  • Xu Y., Menon V., Jugdutt BI Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-e in acutely reperfused myocardial infarction in the dog. Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKCe proteins. JRAAS 2000;1:184-95.[Medline] [Order article via Infotrieve]
  • Schwarz ER, Montino H., Fleischhauer J., Klues HG, vom Dahl J., Hanrath P. Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 1997;11:687-95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hartman JC, Wall TM, Hullinger TG, Shebuski RJ Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.[Web of Science][Medline] [Order article via Infotrieve]
  • Hartman JC, Kurc GM, Hullinger TG, Wall TM, Sheehy RM, Shebuski RJ Inhibition of nitric oxide synthase prevents myocardial protection by ramipril. J Pharmacol Exp Ther 1994;3:1071-6.
  • Liang C-S., Gavras H., Black J., Sherman LG, Hood Jr. WB Renin-angiotensin system inhibition in acute myocardial infarction in dogs. Effects on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 1982;66:1249-55.[Abstract/Free Full Text]
  • Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Jalowy A., Schulz R., Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 1998;93 (Suppl 2):85-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Seyedi N., Xu XB, Nasjletti A., Hintze TH Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.[Abstract/Free Full Text]
  • de Carvalho Frimm C., Sun Y., Weber KT Angiotensin II receptor blockade and myocardial fibrosis of the infarcted rat heart. J Lab Clin Med 1997;129:439-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gaussin V., Schneider MD Surviving infarction one gene at a time. Decreased remodeling and mortality in engineered mice lacking the angiotensin II type 1A receptor. Circulation 1999;100:2043-4.[Free Full Text]
  • Harada K., Sugaya T., Murakami K., Yazaki Y., Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999;100:2093-9.[Abstract/Free Full Text]
  • Yamagishi H., Kim S., Nishikimi T., Takeuchi K., Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25:1369-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Nishikimi T., Yamagishi H., Takeuchi K., Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in hypertensive rats. Cardiovasc Res 1995;29:856-61.[Abstract/Free Full Text]
  • Schieffer B., Wirger A., Meybrunn M. et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.[Abstract/Free Full Text]
  • KohyaT.,Yokoshiki H.,Tohse N. et al. Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ Res 1995;76:892-9.[Abstract/Free Full Text]
  • Gervais M., Richer C., Fornes P., de Gasparo M., Giudicelli J-F. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999;13:635-45.[Web of Science][Medline] [Order article via Infotrieve]
  • van Kats JP, Duncker DJ, Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction. Role of tissue angiotensin II. Circulation 2000;102:1556-63.[Abstract/Free Full Text]
  • DuncanA-M,James GM,Anastasopoulos F., KladisA, Briscoe TA, Campbell DJ Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: Effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J Pharmacol and Exper Ther 1999;289:295-303.
  • Lefkowitz RJ, Rockman HA, Koch WJ Catecholamines, cardiac b-adrenergic receptors, and heart failure. Circulation 2000;101:1634-7.[Free Full Text]
  • Spinale FG, Iannini JP, Mukherjee R., Malton DM, de Gasparo M. Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: Cellular mechanisms of action. J Card Fail 1998;4:325-32.[CrossRef][Medline] [Order article via Infotrieve]
  • Spinale FG, de Gasparo M., Whitebread S. et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure I. Effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385-96.[Abstract/Free Full Text]
  • Krombach RS, Clair MJ, Hendrick JW et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns. Cardiovasc Res 1998;38:631-45.[Abstract/Free Full Text]
  • The Acute Infarction Ramipril Efficacy (AIRE) Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Pfeffer MA, Braunwald E., Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.[Abstract]
  • Pitt B., Segal R., Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the elderly study, ELITE). Lancet 1997;349:747-52.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Circulation 1999;100:1056-64.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S136-S140 (2001)
DOI: 10.1177/14703203010020012401
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schulz, R.
Right arrow Articles by Heusch, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schulz, R.
Right arrow Articles by Heusch, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement